Japan says yes to Boston's DES (drug-eluting stent):
This article was originally published in Clinica
Boston Scientific has gained the all-clear to take its drug-eluting stent DESs to the Japanese market. Its Taxus Express2 paclitaxel-eluting coronary stent was approved by the country's Ministry of Health, Labor and Welfare (MHLW), and Boston plans to launch the product after reimbursement clearance is granted. Japan approved its first DES in 2004 - Johnson & Johnson's sirolimus-eluting stent, Cypher.
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.